vs
FLUSHING FINANCIAL CORP（FFIC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FLUSHING FINANCIAL CORP的季度营收约是REGENXBIO Inc.的1.9倍（$58.8M vs $30.3M），FLUSHING FINANCIAL CORP净利率更高（6.8% vs -221.3%，领先228.2%），FLUSHING FINANCIAL CORP同比增速更快（2597.7% vs 43.0%），FLUSHING FINANCIAL CORP自由现金流更多（$55.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 13.7%）
弗拉格斯塔夫银行（Flagstar Bank, N.A.）是美国区域性金融服务控股集团，总部位于纽约希克斯维尔。2023年该行共运营395家分支机构，并于2024年2月21日完成全部分支机构的品牌统一，全部更名为Flagstar品牌。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FFIC vs RGNX — 直观对比
营收规模更大
FFIC
是对方的1.9倍
$30.3M
营收增速更快
FFIC
高出2554.7%
43.0%
净利率更高
FFIC
高出228.2%
-221.3%
自由现金流更多
FFIC
多$108.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
13.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $58.8M | $30.3M |
| 净利润 | $4.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 13.3% | -190.0% |
| 净利率 | 6.8% | -221.3% |
| 营收同比 | 2597.7% | 43.0% |
| 净利润同比 | 108.2% | -31.2% |
| 每股收益（稀释后） | $0.12 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FFICRGNX
| Q4 25 | $58.8M | $30.3M | ||
| Q3 25 | $58.6M | $29.7M | ||
| Q2 25 | $63.5M | $21.4M | ||
| Q1 25 | $58.1M | $89.0M | ||
| Q4 24 | $2.2M | $21.2M | ||
| Q3 24 | $51.9M | $24.2M | ||
| Q2 24 | $47.0M | $22.3M | ||
| Q1 24 | $45.5M | $15.6M |
净利润FFICRGNX
| Q4 25 | $4.0M | $-67.1M | ||
| Q3 25 | $10.4M | $-61.9M | ||
| Q2 25 | $14.2M | $-70.9M | ||
| Q1 25 | $-9.8M | $6.1M | ||
| Q4 24 | $-49.2M | $-51.2M | ||
| Q3 24 | $8.9M | $-59.6M | ||
| Q2 24 | $5.3M | $-53.0M | ||
| Q1 24 | $3.7M | $-63.3M |
毛利率FFICRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FFICRGNX
| Q4 25 | 13.3% | -190.0% | ||
| Q3 25 | 23.4% | -176.3% | ||
| Q2 25 | 29.8% | -296.3% | ||
| Q1 25 | -10.2% | 13.6% | ||
| Q4 24 | -3296.2% | -242.1% | ||
| Q3 24 | 22.1% | -256.6% | ||
| Q2 24 | 15.2% | -251.3% | ||
| Q1 24 | 11.0% | -408.8% |
净利率FFICRGNX
| Q4 25 | 6.8% | -221.3% | ||
| Q3 25 | 17.8% | -208.3% | ||
| Q2 25 | 22.4% | -331.8% | ||
| Q1 25 | -16.9% | 6.8% | ||
| Q4 24 | -2258.9% | -241.3% | ||
| Q3 24 | 17.2% | -246.3% | ||
| Q2 24 | 11.3% | -237.7% | ||
| Q1 24 | 8.1% | -405.4% |
每股收益（稀释后）FFICRGNX
| Q4 25 | $0.12 | $-1.30 | ||
| Q3 25 | $0.30 | $-1.20 | ||
| Q2 25 | $0.41 | $-1.38 | ||
| Q1 25 | $-0.29 | $0.12 | ||
| Q4 24 | $-1.67 | $-0.99 | ||
| Q3 24 | $0.30 | $-1.17 | ||
| Q2 24 | $0.18 | $-1.05 | ||
| Q1 24 | $0.12 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $708.0M | $102.7M |
| 总资产 | $8.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FFICRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益FFICRGNX
| Q4 25 | $708.0M | $102.7M | ||
| Q3 25 | $711.2M | $161.5M | ||
| Q2 25 | $706.4M | $213.7M | ||
| Q1 25 | $702.9M | $274.2M | ||
| Q4 24 | $724.5M | $259.7M | ||
| Q3 24 | $666.9M | $301.4M | ||
| Q2 24 | $665.3M | $348.3M | ||
| Q1 24 | $669.8M | $390.7M |
总资产FFICRGNX
| Q4 25 | $8.7B | $453.0M | ||
| Q3 25 | $8.9B | $525.2M | ||
| Q2 25 | $8.8B | $581.0M | ||
| Q1 25 | $9.0B | $490.9M | ||
| Q4 24 | $9.0B | $466.0M | ||
| Q3 24 | $9.3B | $519.1M | ||
| Q2 24 | $9.1B | $569.4M | ||
| Q1 24 | $8.8B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 94.9% | -174.0% |
| 资本支出强度资本支出/营收 | 8.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 15.16× | — |
| 过去12个月自由现金流最近4个季度 | $104.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FFICRGNX
| Q4 25 | $61.0M | $-52.3M | ||
| Q3 25 | $19.6M | $-56.0M | ||
| Q2 25 | $25.8M | $-49.3M | ||
| Q1 25 | $6.9M | $33.6M | ||
| Q4 24 | $12.4M | $-31.6M | ||
| Q3 24 | $5.4M | $-40.5M | ||
| Q2 24 | $9.6M | $-45.5M | ||
| Q1 24 | $-6.2M | $-55.5M |
自由现金流FFICRGNX
| Q4 25 | $55.8M | $-52.8M | ||
| Q3 25 | $19.3M | $-56.5M | ||
| Q2 25 | $24.4M | $-49.7M | ||
| Q1 25 | $5.2M | $32.6M | ||
| Q4 24 | $10.1M | $-32.7M | ||
| Q3 24 | $4.8M | $-40.9M | ||
| Q2 24 | $8.8M | $-46.0M | ||
| Q1 24 | $-6.5M | $-56.0M |
自由现金流率FFICRGNX
| Q4 25 | 94.9% | -174.0% | ||
| Q3 25 | 33.0% | -189.9% | ||
| Q2 25 | 38.5% | -232.8% | ||
| Q1 25 | 8.9% | 36.6% | ||
| Q4 24 | 463.4% | -154.2% | ||
| Q3 24 | 9.3% | -168.9% | ||
| Q2 24 | 18.7% | -206.2% | ||
| Q1 24 | -14.3% | -358.5% |
资本支出强度FFICRGNX
| Q4 25 | 8.9% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 2.1% | 1.8% | ||
| Q1 25 | 2.9% | 1.2% | ||
| Q4 24 | 106.0% | 5.1% | ||
| Q3 24 | 1.1% | 1.3% | ||
| Q2 24 | 1.7% | 2.1% | ||
| Q1 24 | 0.6% | 3.6% |
现金转化率FFICRGNX
| Q4 25 | 15.16× | — | ||
| Q3 25 | 1.87× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 1.80× | — | ||
| Q1 24 | -1.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
